| __timestamp | Incyte Corporation | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 10811000 |
| Thursday, January 1, 2015 | 196614000 | 33001000 |
| Friday, January 1, 2016 | 303251000 | 64936000 |
| Sunday, January 1, 2017 | 366406000 | 99909000 |
| Monday, January 1, 2018 | 434407000 | 127724000 |
| Tuesday, January 1, 2019 | 468711000 | 161524000 |
| Wednesday, January 1, 2020 | 516922000 | 182933000 |
| Friday, January 1, 2021 | 739560000 | 219982000 |
| Saturday, January 1, 2022 | 1002140000 | 278139000 |
| Sunday, January 1, 2023 | 1161300000 | 309799000 |
| Monday, January 1, 2024 | 1242157000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Incyte Corporation and Ultragenyx Pharmaceutical Inc. have shown contrasting trends in their SG&A expenditures. From 2014 to 2023, Incyte's SG&A expenses surged by approximately 600%, reflecting its aggressive expansion strategy. In contrast, Ultragenyx's expenses grew by around 280%, indicating a more measured approach.
Incyte's expenses peaked in 2023, reaching nearly four times that of Ultragenyx, highlighting its significant investment in administrative capabilities. This disparity underscores the different strategic priorities of these companies. While Incyte focuses on scaling operations, Ultragenyx appears to prioritize cost efficiency. Understanding these trends offers valuable insights into how biotech firms balance growth and operational efficiency.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Incyte Corporation vs Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Incyte Corporation and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?